Bo Liu

Bo Liu


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2023 in Emergency Medicine International
Verified
Journal Article
Open access
PDF file
XPXue-Bin Pei
Xue-Bin Pei
BLBo Liu
Bo Liu
Sepsis is defined as a kind of life-threatening organ dysfunction due to a dysregulated host immune response to infection and is a leading cause of mortality in the intensive care unit. Sepsis-induced myocardial dysfunction, also called septic cardiomyopathy, is a common and serious complication in patients with sepsis, which may indicate a bad prognosis. Although efforts have been made to uncover the pathophysiology of septic cardiomyopathy, a number of uncertainties remain. This article sought to review available literature to summarize the existing knowledge on current diagnostic tools and biomarkers, pathogenesis, and treatments for septic cardiomyopathy.

26 April 2024 in Virology Journal
Verified
Journal Article
Open access
PDF file
ZWZhipeng Wu
Zhipeng Wu
NGNan Geng
Nan Geng
ZLZhao Liu
Zhao Liu
WPWen Pan
Wen Pan
YZYueke Zhu
Yueke Zhu
BLBo Liu
Bo Liu
Background: There is still limited research on the prognostic value of Presepsin as a biomarker for predicting the outcome of COVID-19 patients. Additionally, research on the combined predictive value of Presepsin with clinical scoring systems and inflammation markers for disease prognosis is lacking. Methods: A total of 226 COVID-19 patients admitted to Beijing Youan Hospital’s emergency department from May to November 2022 were screened. Demographic information, laboratory measurements, and blood samples for Presepsin levels were collected upon admission. The predictive value of Presepsin, clinical scoring systems, and inflammation markers for 28-day mortality was analyzed. Results: A total of 190 patients were analyzed, 83 (43.7%) were mild, 61 (32.1%) were moderate, and 46 (24.2%) were severe/critically ill. 23 (12.1%) patients died within 28 days. The Presepsin levels in severe/critical patients were significantly higher compared to moderate and mild patients (p < 0.001). Presepsin showed significant predictive value for 28-day mortality in COVID-19 patients, with an area under the ROC curve of 0.828 (95% CI: 0.737–0.920). Clinical scoring systems and inflammation markers also played a significant role in predicting 28-day outcomes. After Cox regression adjustment, Presepsin, qSOFA, NEWS2, PSI, CURB-65, CRP, NLR, CAR, and LCR were identified as independent predictors of 28-day mortality in COVID-19 patients (all p-values < 0.05). Combining Presepsin with clinical scoring systems and inflammation markers further enhanced the predictive value for patient prognosis. Conclusion: Presepsin is a favorable indicator for the prognosis of COVID-19 patients, and its combination with clinical scoring systems and inflammation markers improved prognostic assessment.

1 June 2024 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
NGNan Geng
Nan Geng
ZWZhipeng Wu
Zhipeng Wu
ZLZhao Liu
Zhao Liu
WPWen Pan
Wen Pan
YZYueke Zhu
Yueke Zhu
BLBo Liu
Bo Liu
Background: Research on biomarkers associated with the severity and adverse prognosis of COVID-19 can be beneficial for improving patient outcomes. However, there is limited research on the role of soluble TREM-1 (sTREM-1) in predicting the severity and prognosis of COVID-19 patients. Methods: A total of 115 COVID-19 patients admitted to the emergency department of Beijing Youan Hospital from February to May 2023 were included in the study. Demographic information, laboratory measurements, and blood samples for sTREM-1 levels were collected upon admission. Results: Our study found that sTREM-1 levels in the plasma of COVID-19 patients increased with the severity of the disease (moderate vs mild, p=0.0013; severe vs moderate, p=0.0195). sTREM-1 had good predictive value for disease severity and 28-day mortality (area under the ROC curve was 0.762 and 0.805, respectively). sTREM-1 also exhibited significant correlations with age, body temperature, respiratory rate, PaO2/FiO2, PCT, CRP, and CAR. Ultimately, through multivariate logistic regression analysis, we determined that sTREM-1 (OR 1.008, 95% CI: 1.002– 1.013, p=0.005), HGB (OR 0.966, 95% CI: 0.935– 0.998, p=0.036), D-dimer (OR 1.001, 95% CI: 1.000– 1.001, p=0.009), and CAR (OR 1.761, 95% CI: 1.154– 2.688, p=0.009) were independent predictors of 28-day mortality in COVID-19 patients. The combination of these four markers yielded a strong predictive value for 28-day mortality in COVID-19 cases with an AUC of 0.919 (95% CI: 0.857 − 0.981). Conclusion: sTREM-1 demonstrated good predictive value for disease severity and 28-day mortality, serving as an independent prognostic factor for adverse patient outcomes. In the future, we anticipate conducting large-scale multicenter studies to validate our research findings.

1 March 2025 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
CLChunlian Lai
Chunlian Lai
YWYingfei Wang
Yingfei Wang
FSFengwei Shi
Fengwei Shi
NGNan Geng
Nan Geng
ZLZhao Liu
Zhao Liu
BLBo Liu
Bo Liu
Background: Coronavirus Disease 2019 (COVID-19), caused by the novel coronavirus, has posed a significant threat to global public health, leading to substantial morbidity, mortality, and strain on healthcare resources. Despite the availability of vaccines and treatments, effective biomarkers for predicting disease progression remain limited. This study aimed to investigate the prognostic value of soluble fms-like tyrosine kinase-1 (sFlt-1) in COVID-19 patients. Methods: A prospective cohort study was conducted involving 154 COVID-19 patients, with comprehensive clinical data and laboratory parameters analyzed to evaluate the effectiveness of sFlt-1 in determining disease severity and prognosis. Results: The results revealed that sFlt-1 levels correlated significantly with disease severity, showing higher levels in severe/critical cases compared to mild cases (P< 0.05). In the deceased group, sFlt-1 levels were notably higher compared to survivors, with an area under the curve (AUC) of 0.840, showing good predictive power for 28-day mortality. Multivariable logistic regression identified sFlt-1, respiratory rate, and albumin as independent prognostic factors, with a combined AUC of 0.938 (95% CI: 0.886– 0.991) for predicting mortality risk. Conclusion: These findings underscore the potential of sFlt-1 as a valuable biomarker for clinical decision-making in managing COVID-19 patients. Future studies should focus on the clinical application of sFlt-1 and explore its underlying mechanisms to enhance patient management strategies.

13 May 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
ZLZhao Liu
Zhao Liu
FSFengwei Shi
Fengwei Shi
NGNan Geng
Nan Geng
WPWen Pan
Wen Pan
BLBo Liu
Bo Liu
QMQinghua Meng
Qinghua Meng
Background: Liver cirrhosis complicated by sepsis is associated with significant immune dysfunction and high mortality rates. Programmed cell death protein 1 (PD-1) expression on lymphocytes has been implicated in immune exhaustion, but its prognostic significance in this population remains unclear. Objective: This study aimed to evaluate the prognostic value of lymphocyte PD-1 expression in combination with clinical scoring systems, such as the Child-Pugh score and chronic liver failure-sequential organ failure assessment (CLIF-SOFA), for predicting disease severity and 28-day mortality in patients with cirrhosis complicated by sepsis. Methods: This prospective study included 86 patients with cirrhosis and sepsis admitted to Beijing You’an Hospital between June 2023 and May 1, 2024. Fresh whole blood was collected at enrollment, and peripheral blood mononuclear cells (PBMCs) were isolated for flow cytometric analysis of PD-1 expression on CD3+, CD4+, and CD8+ lymphocytes. Clinical parameters, scoring systems, and laboratory data were collected to assess their correlation with PD-1 expression and patient outcomes. Results: Of the 86 patients, 38 (44.2%) survived, while 48 (55.8%) died within 28 days. Non-survivors exhibited higher PD-1 expression on CD3+, CD4+, and CD8+ lymphocytes, as well as worse Child-Pugh and CLIF-SOFA scores (all p < 0.05). A significant positive correlation was observed between lymphocyte PD-1 expression and disease severity scores. Multivariate logistic regression analysis identified PD-1 expression on CD3+, CD4+, and CD8+ lymphocytes as independent predictors of 28-day mortality. Combining lymphocyte PD-1 expression with clinical scoring systems improved the predictive accuracy for septic shock and mortality. Conclusion: Lymphocyte PD-1 expression is associated with disease severity and poor prognosis in patients with cirrhosis complicated by sepsis. Combining PD-1 expression with traditional scoring systems enhances risk stratification and may provide a more comprehensive tool for predicting outcomes in this high-risk population.

9 September 2026 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
YCYingying Cui
Yingying Cui
BLBo Liu
Bo Liu
NGNan Geng
Nan Geng
ZLZhao Liu
Zhao Liu
WPWen Pan
Wen Pan
HLHaoqi Li
Haoqi Li
Objective: This study aimed to investigate the predictive value of the disseminated intravascular coagulation (DIC) score combined with lactate (Lac) for the prognosis of patients with cirrhosis and variceal upper gastrointestinal bleeding (VUGIB). Methods: In this retrospective cohort study, we enrolled 409 patients with liver cirrhosis and VUGIB who were admitted to Beijing You'an Hospital, Capital Medical University, between July 2023 and July 2025.The predictive outcomes were 28-day mortality, multiple organ dysfunction syndrome (MODS), and admission to the intensive care unit (ICU). Univariate baseline comparisons were performed. A multivariable logistic primary model was constructed, and two types of sensitivity analyses were established. The independence of the DIC score as a prognostic factor was assessed using Wald, likelihood-ratio, and interaction tests. Receiver operating characteristic (ROC) curves were plotted, and the areas under the curves (AUCs) of the models were compared using DeLong's test. Internal validation was conducted with 1,000 bootstrap resamples. Model calibration was evaluated using the Hosmer-Lemeshow test and calibration curves. The optimal cut-off value was determined via 10-fold cross-validation, and survival differences were analyzed using the Kaplan–Meier method. Decision curve analysis was performed to evaluate the net clinical benefit. Results: Univariate analysis revealed that lactate, DIC score, and various liver function and bleeding scores differed significantly among the three prognostic outcome groups (all P < 0.05). After adjusting for covariates, DIC score was identified as an independent risk factor for all three outcomes, and its predictive value was independent of Child-Pugh and MELD-Na scores, with no interaction between them. ROC analysis showed that the combined lactate + DIC model had the best discriminative performance (AUC for mortality = 0.892, for MODS = 0.889, for ICU admission = 0.851), and DeLong's test confirmed that it was superior to most conventional scores. After bootstrap correction, the model exhibited no significant optimism bias, and the Hosmer-Lemeshow test indicated good calibration. Stratification by the cross-validation-derived cutoff value revealed statistically significant differences in 28-day survival between high-and low-risk patients across all outcome groups (log-rank P < 0.001). Decision curve analysis demonstrated that the lactate + DIC model provided higher net clinical benefit than DIC score alone. Conclusion: The combination of DIC score and lactate independently predicts the risks of 28-day mortality, MODS, and ICU admission in patients with liver cirrhosis and VUGIB. Multidimensional validation demonstrated that this model exhibited superior discrimination, calibration, and net clinical benefit compared with any single score, and thus can be applied for early risk stratification at admission.